Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...

Novartis on Tuesday said it had received approval in Switzerland for Coartem, which it said was the first drug to treat ...

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants.

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Malaria caused 597,000 deaths worldwide in 2023, with children under 5 accounting for 76 percent of all malaria deaths in the ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

Novartis has won approval in Switzerland for the world’s first malaria drug for newborns and infants, creating a new weapon ...

Novartis' Coartem Baby wins Swiss approval as the first malaria drug for newborns under 5 kg, offering safer dosing and ...